Figure 1.
Figure 2.
Figure 3.
Figure 4.
Comparison of mean age of hematologic malignancy patients pre-COVID-19 and post-COVID-19 pandemic
| Disease type | Pre-COVID | Post-COVID | P | ||
|---|---|---|---|---|---|
| Mean ± SD | n | Mean ± SD | n | ||
| MPN | 54.6 ± 16.9 | 130 | 54.2 ± 19.8 | 294 | 0.984 |
| MDS/MPN overlap syndromes | 69.4 ± 8.9 | 7 | 69.0 ± 16.3 | 33 | 0.970 |
| MDS | 62.5 ± 24.3 | 217 | 62.8 ± 22.8 | 588 | 0.988 |
| AML | 50.5 ± 17.8 | 132 | 48.6 ± 21.4 | 247 | 0.914 |
| Acute leukemia (unclassified) | 20.4 ± 20.3 | 17 | 23.5 ± 26.3 | 63 | 0.879 |
| ALL | 30.1 ± 23.0 | 45 | 26.6 ± 18.4 | 157 | 0.868 |
| MM | 63.6 ± 13.5 | 96 | 64.4 ± 16.0 | 237 | 0.949 |
| CLL | 70.7 ± 10.6 | 10 | 68.1 ± 25.1 | 35 | 0.858 |
| Lymphoma | 52.0 ± 20.5 | 34 | 48.3 ± 25.5 | 129 | 0.859 |
Number of bone marrow samples received by Cytogenetic laboratory during 2018–2024
| Year | Total bone marrow samples | Total cases included in the report | Male | Female |
|---|---|---|---|---|
| 2018 | 622 | 394 | 212 | 182 |
| 2019 | 704 | 452 | 231 | 221 |
| 2020 | 623 | 426 | 226 | 200 |
| 2021 | 495 | 425 | 218 | 207 |
| 2022 | 601 | 412 | 209 | 203 |
| 2023 | 730 | 485 | 258 | 227 |
| January 1–October 31, 2024 | 791 | 483 | 217 | 266 |
| Total | 4,566 | 3,077 | 1,571 | 1,506 |
Comparison of hematologic disease frequencies pre- and post-COVID-19 pandemic using OR and Fisher’s exact test
| Disease type | OR | 95% CI | Fisher’s P-value |
|---|---|---|---|
| MPN | 0.79 | 0.64–0.98 | 0.03389 |
| MDS/MPN | 1.68 | 0.74–3.81 | 0.27847 |
| MDS | 0.96 | 0.81–1.13 | 0.63511 |
| AML | 0.65 | 0.52–0.80 | 0.00014 |
| Acute leukemia | 1.32 | 0.77–2.27 | 0.37042 |
| ALL | 1.25 | 0.89–1.75 | 0.22189 |
| MM | 0.87 | 0.68–1.11 | 0.27557 |
| CLL | 1.25 | 0.62–2.52 | 0.61306 |
| Lymphoma | 1.36 | 0.93–1.99 | 0.12476 |